# Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors

> **NCT00079352** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** alvocidib
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00079352
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079352, "Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00079352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*